Production (Stage)
ABVC BioPharma, Inc.
ABVC
$1.15
-$0.06-4.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -96.42% | |||
| Total Other Revenue | -- | -224.73% | |||
| Total Revenue | -- | -99.49% | |||
| Cost of Revenue | -- | -100.00% | |||
| Gross Profit | -- | -99.49% | |||
| SG&A Expenses | 118.38% | 0.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | 369.23% | |||
| Total Operating Expenses | 81.56% | 18.36% | |||
| Operating Income | -82.51% | -668.41% | |||
| Income Before Tax | -832.51% | 196.27% | |||
| Income Tax Expenses | -- | -100.00% | |||
| Earnings from Continuing Operations | -832.51% | 195.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 1.69% | 291.97% | |||
| Net Income | -467.25% | 222.88% | |||
| EBIT | -82.51% | -668.41% | |||
| EBITDA | -85.76% | -600.41% | |||
| EPS Basic | -423.56% | 216.00% | |||
| Normalized Basic EPS | -272.32% | 260.91% | |||
| EPS Diluted | -423.56% | 187.00% | |||
| Normalized Diluted EPS | -272.32% | 260.91% | |||
| Average Basic Shares Outstanding | 13.36% | 6.44% | |||
| Average Diluted Shares Outstanding | 13.36% | 6.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||